# Mitochondrial Dysfunction Brief: References

1\. Barbiroli B, Frassineti C, Martinelli P, et al. Coenzyme Q10
improves mitochondrial respiration in patients with mitochondrial
cytopathies. An in vivo study on brain and skeletal muscle by
phosphorous magnetic resonance spectroscopy. *Cellular and Molecular
Biology*. 1997;43:741-9.

2\. Barbiroli B, Iotti S, Lodi R. Improved brain and muscle
mitochondrial respiration with CoQ. An in vivo study by 31P-MR
spectroscopy in patients with mitochondrial cytopathies. *Biofactors*.
1999;9:253-60.

3\. Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial
encephalomyopathy associated with a muscle coenzyme Q10 deficiency.
*Journal of the Neurological Sciences*. 1998;156:41-6.

4\. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial
encephalomyopathies. Short-term double-blind, crossover study. *European
Neurology*. 1997;37:212-8.

5\. Darley-Usmar VM, Kennaway NG, Buist NR, Capaldi RA. Deficiency in
ubiquinone cytochrome c reductase in a patient with mitochondrial
myopathy and lactic acidosis. *Proc Natl Acad Sci U S A*.
1983;80:5103-6.

6\. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10
reverses pathological phenotype and reduces apoptosis in familial CoQ10
deficiency. *Neurology*. 2001;57:515-8.

7\. England JD, Walsh JC, Stewart P, Boyd I, Rohan A, Halmagyi GM.
Mitochondrial myopathy developing on treatment with the HMG CoA
reductase inhibitors\--simvastatin and pravastatin \[letter\].
*Australian and New Zealand Journal of Medicine*. 1995;25:374-5.

8\. Fosslien E. Mitochondrial medicine\--molecular pathology of
defective oxidative phosphorylation. *Ann Clin Lab Sci*. 2001;31:25-67.

9\. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency
in familial mitochondrial encephalomyopathy. *Proc Natl Acad Sci U S A*.
1989;86:2379-82.

10\. Takusa Y, Yamaguchi S. \[Myopathies with miscellaneous disorders
related to mitochondrial fatty acid oxidation: defective synthesis of
ketone body, long-chain fatty acid transport defect, and muscular
coenzyme Q10 deficiency\]. *Ryoikibetsu Shokogun Shirizu*. 2001:90-4.

11\. Tedeschi D, Lombardi V, Mancuso M, et al. Potential involvement of
ubiquinone in myotonic dystrophy pathophysiology: new diagnostic
approaches for new rationale therapeutics. *Neurol Sci*.
2000;21:S979-80.

12\. Fukuda K, Nisenbaum R, Stewart G, et al. Chronic multisymptom
illness affecting Air Force veterans of the Gulf War. *JAMA*.
1998;280:981-988.

13\. Bowman PD, Schuschereba ST, Johnson TW, et al. Myopathic changes in
diaphragm of rats fed pyridostigmine bromide subchronically. *Fundam
Appl Toxicol*. 1989;13:110-7.

14\. Glass-Marmor L, Chen-Zion M, Beitner R. Effects of carbamylcholine
and pyridostigmine on cytoskeleton-bound and cytosolic
phosphofructokinase and ATP levels in different rat tissues. *Gen
Pharmacol*. 1996;27:1241-6.

15\. Glass-Marmor L, Beitner R. Effects of carbamylcholine and
pyridostigmine on mitochondrial-bound hexokinase in skeletal muscle and
heart. *Biochem Mol Med*. 1996;57:67-70.

16\. Hudson CS, Foster RE, Kahng MW. Neuromuscular toxicity of
pyridostigmine bromide in the diaphragm, extensor digitorum longus, and
soleus muscles of the rat. *Fundam Appl Toxicol*. 1985;5:S260-9.

17\. Kato T, Sugiyama S, Hanaki Y, et al. Role of acetylcholine in
pyridostigmine-induced myocardial injury: possible involvement of
parasympathetic nervous system in the genesis of cardiomyopathy. *Arch
Toxicol*. 1989;63:137-43.

18\. Schuschereba ST, Bowman PD, Vargas JA, Johnson TW, Woo FJ, McKinney
L. Myopathic alterations in extraocular muscle of rats subchronically
fed pyridostigmine bromide. *Toxicol Pathol*. 1990;18:387-95.

19\. Kawabuchi M. Neostigmine myopathy is a calcium ion-mediated
myopathy initially affecting the motor end-plate. *J Neuropathol Exp
Neurol*. 1982;41:298-314.

20\. Babu SR, Buckenmeyer P, Knowlton RG, Somani SM. Effect of
physostigmine on plasma lactate and pyruvate in untrained/trained rats.
*Pharmacol Biochem Behav*. 1992;42:67-73.

21\. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs
and mitochondrial function: effects of HMG-CoA reductase inhibitors on
serum ubiquinone and blood lactate/pyruvate ratio. *British Journal of
Clinical Pharmacology*. 1996;42:333-7.

22\. King BF, Somani SM. Distribution of physostigmine and metabolites
in brain subcellular fractions of the rat. *Life Sci*. 1987;41:2007-15.

23\. Li L, Gunaseker PG, Borowitz JL, Isom GE. Pyridostigmine-induced
acute and delayed neuronal apoptosis \[abstract\]. *Soc Toxicol
Abstract*. 1999.

24\. Li L, Gunasekar PG, Borowitz JL, Isom GE. Muscarinic
receptor-mediated pyridostigmine-induced neuronal apoptosis.
*Neurotoxicology*. 2000;21:541-52.

25\. Isom GE. Pyridostigmine-induced neurodegeneration: role of neuronal
apoptosis. In: The Research Working Group of the Persian Gulf Veterans
Coordinating Board, ed. *Annual Report to Congress: Federally Sponsored
Research on Gulf War Veterans\' Illnesses for 1998. Appendices*;
1999:100.

26\. Li L, Shou Y, Borowitz JL, Isom GE. Reactive oxygen species mediate
pyridostigmine-induced neuronal apoptosis: involvement of muscarinic and
NMDA receptors. *Toxicol Appl Pharmacol*. 2001;177:17-25.

27\. Quillet-Mary A, Jaffrezou JP, Mansat V, Bordier C, Naval J, Laurent
G. Implication of mitochondrial hydrogen peroxide generation in
ceramide-induced apoptosis. *J Biol Chem*. 1997;272:21388-95.

28\. Haley RW, Marshall WW, McDonald GG, Daugherty MA, Petty F,
Fleckenstein JL. Brain abnormalities in Gulf War syndrome: Evaluation
with 1H MR spectroscopy. *Radiology*. 2000;215:807-817.

29\. Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War
syndrome. *Exp Mol Pathol*. 2000;68:55-64.

30\. Powell MF, Newman MJ. Chapter 8. Adjuvant properties of aluminum
and calcium compounds. *Vaccine Design. The Subunit and Adjuvant
Approach.* New York: Plenum Press; 1995.

31\. Melinda Plaisier, FDA Associate Commissioner of Legislation, Letter
to Congressmand Jack Metcalf, 20 March 2000. Cited in: \[Committee on
Government Reform Hearings for the United States House of
Representatives, 2000 #1320\]. 2000.

32\. Ivins B, Fellows P, Pitt L, et al. Experimental anthrax vaccines:
efficacy of adjuvants combined with protective antigen against an
aerosol Bacillus anthracis spore challenge in guinea pigs. *Vaccine*.
1995;13:1779-84.

33\. Ivins B, et al. Adjuvant efficacy in experimental anthrax vaccines:
Protection studies in guinea pigs. *Abstracts of the 91st General
Meeting of the American Society for Microbiology*. 1991:121.

34\. Matsumoto G. The Pentagon\'s toxic secret. *Vanity Fair*;
1999:83-96.

35\. Tomich N. Anthrax vaccine program scrutiny intensifies. *U.S.
Medicine*. 2000;36:1,32,33,36.

36\. Carlson BC, Jansson AM, Larsson A, Bucht A, Lorentzen JC. The
endogenous adjuvant squalene can induce a chronic T-cell-mediated
arthritis in rats. *Am J Pathol*. 2000;156:2057-65.

37\. Gajkowska B, Smialek M, Ostrowski RP, Piotrowski P. The
experimental squalene encephaloneuropathy in the rat. *Exp Toxicol
Pathol*. 1999;51:75-80.

38\. Lorentzen JC. Identification of arthritogenic adjuvants of self and
foreign origin. *Scand J Immunol*. 1999;49:45-50.

39\. Sverdrup B, Klareskog L, Kleinau S. Common commercial cosmetic
products induce arthritis in the DA rat. *Environ Health Perspect*.
1998;106:27-32.

40\. Dijkstra J, Swartz GM, Jr., Raney JJ, et al. Interaction of
anti-cholesterol antibodies with human lipoproteins. *J Immunol*.
1996;157:2006-13.

41\. Ordovas JM. Anticholesterol antibodies and plaque formation. *Nutr
Rev*. 1996;54:124-7.

42\. Alving CR, Swartz GM, Jr., Wassef NM, et al. Immunization with
cholesterol-rich liposomes induces anti-cholesterol antibodies and
reduces diet-induced hypercholesterolemia and plaque formation. *J Lab
Clin Med*. 1996;127:40-9.

43\. Alving CR, Wassef NM, Potter M. Antibodies to cholesterol:
biological implications of antibodies to lipids. *Curr Top Microbiol
Immunol*. 1996;210:181-6.

44\. Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total
cholesterol, high-density lipoprotein, and apolipoprotein A1 in
association with anticardiolipin antibodies in patients with systemic
lupus erythematosus. *Arthritis Rheum*. 1993;36:1566-74.

45\. Alving CR, Swartz GM, Jr. Antibodies to cholesterol, cholesterol
conjugates and liposomes: implications for atherosclerosis and
autoimmunity. *Crit Rev Immunol*. 1991;10:441-53.

46\. Alving CR. Antibodies to liposomes, phospholipids, and cholesterol:
implications for autoimmunity, atherosclerosis, and aging. *Prog Clin
Biol Res*. 1990;343:41-51.

47\. Swartz GM, Jr., Gentry MK, Amende LM, Blanchette-Mackie EJ, Alving
CR. Antibodies to cholesterol. *Proc Natl Acad Sci U S A*.
1988;85:1902-6.

48\. Folkers K, Nilsson JL. \[Coenzyme Q regarded as a vitamin\]. *Nord
Med*. 1970;83:489-93.

49\. Estornell E, Tormo JR, Marin P, Renau-Piqueras J, Timoneda J,
Barber T. Effects of vitamin A deficiency on mitochondrial function in
rat liver and heart. *Br J Nutr*. 2000;84:927-34.

50\. Anderson SS, Lyle IG, Paterson R. Electron transfer across
membranes using vitamin K1 and coenzyme Q10 as carrier molecules.
*Nature*. 1976;259:147-8.

51\. Sobreira C, Hirano M, Shanske S, et al. Mitochondrial
encephalomyopathy with coenzyme Q10 deficiency. *Neurology*.
1997;48:1238-43.

52\. DiMauro S, Bonilla E, Davidson M, Hirano M, Schon EA. Mitochondria
in neuromuscular disorders. *Biochimica et Biophysica Acta*.
1998;1366:199-210.

53\. Suzuki Y, Kadowaki H, Atsumi Y, et al. A case of diabetic
amyotrophy associated with 3243 mitochondrial tRNA(leu; UUR) mutation
and successful therapy with coenzyme Q10. *Endocrine Journal*.
1995;42:141-5.

54\. Hansen IL, Iwamoto Y, Kishi T, Folkers K, Thompson LE.
Bioenergetics in clinical medicine. IX. Gingival and leucocytic
deficiencies of coenzyme Q10 in patients with periodontal disease. *Res
Commun Chem Pathol Pharmacol*. 1976;14:729-38.

55\. Wilkinson EG, Arnold RM, Folkers K, Hansen I, Kishi H.
Bioenergetics in clinical medicine. II. Adjunctive treatment with
coenzyme Q in periodontal therapy. *Res Commun Chem Pathol Pharmacol*.
1975;12:111-23.

56\. Folkers K, Simonsen R. Two successful double-blind trials with
coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic
atrophies. *Biochimica et Biophysica Acta*. 1995;1271:281-6.

57\. Kuz\'menko IV, Donchenko GV, Kovalenko VN, Gololobov AD, Tarasova
NV. \[Efficiency of ubiquinone and p-oxybenzoic acid in prevention of
E-hypovitaminosis-induced development of muscular dystrophy\]. *Ukr
Biokhim Zh*. 1981;53:73-9.

58\. Shimomura Y, Suzuki M, Sugiyama S, Hanaki Y, Ozawa T. Protective
effect of coenzyme Q10 on exercise-induced muscular injury. *Biochem
Biophys Res Commun*. 1991;176:349-55.

59\. Muller DP, Lloyd JK, Wolff OH. Vitamin E and neurological function:
abetalipoproteinaemia and other disorders of fat absorption. *Ciba Found
Symp*. 1983;101:106-21.

60\. Muller DPR, Lloyd JK, Bird A. Long-term management of
abetalipoproteinemia. Possible role for vitamin E. *Arch Dis Child*.
1977;52:209-14.

61\. Azizi E, Zaidman JL, Eschar J, Aszeinberg A. Abetalipoproteinemia
treated with parenteral and oral vitamin A and E and with medium chain
triglycerides. *Acta Pediatr Scand*. 1978; 67:797-801.

62\. Hegele RA, Angel A. Arrest of neuropathy and myopathy in
abetalipoproteinemia with high-dose vitamin E therapy. *Can Med Assoc
J*. 1985;132:41-4.

63\. Iannaccone ST, Sokol RJ. Vitamin E deficiency in neuropathy of
abetalipoproteinemia. *Neurology*. 1986;36:1009.

64\. Alleva R, Tomasetti M, Andera L, et al. Coenzyme Q blocks
biochemical but not receptor-mediated apoptosis by increasing
mitochondrial antioxidant protection. *FEBS Lett*. 2001;503:46-50.

65\. Fernandez-Ayala DJ, Martin SF, Barroso MP, et al. Coenzyme Q
protects cells against serum withdrawal-induced apoptosis by inhibition
of ceramide release and caspase-3 activation. *Antioxid Redox Signal*.
2000;2:263-75.

66\. Kagan T, Davis C, Lin L, Zakeri Z. Coenzyme Q10 can in some
circumstances block apoptosis, and this effect is mediated through
mitochondria. *Ann N Y Acad Sci*. 1999;887:31-47.

67\. Mosca L, Marcellini S, Perluigi M, et al. Modulation of apoptosis
and improved redox metabolism with the use of a new antioxidant formula.
*Biochem Pharmacol*. 2002;63:1305-14.

68\. Buckenmeyer PJ, Babu SR, Knowlton RG, Somani SM. Effect of
concurrent exercise and physostigmine on lactate and pyruvate in plasma,
muscle, and brain tissue of rats. *Pharmacol Biochem Behav*.
1994;47:779-88.

69\. Phillips P, et al. Title Not Yet on Current Contents. *Annals of
Internal Medicine*. 2002;Oct 1, 2002:Pages to be secured.

70\. Ackrell BA, Maguire JJ, Dallman PR, Kearney EB. Effect of iron
deficiency on succinate- and NADH-ubiquinone oxidoreductases in skeletal
muscle mitochondria. *J Biol Chem*. 1984;259:10053-9.

71\. Shingwekar AG, Mohanram M, Reddy V. Effect of zinc supplementation
on plasma levels of vitamin A and retinol-binding protein in
malnourished children. *Clin Chim Acta*. 1979;93:97-100.

72\. Vadhanavikit S, Ganther HE. Decreased ubiquinone levels in tissues
of rats deficient in selenium. *Biochem Biophys Res Commun*.
1993;190:921-6.

73\. Pedersen HS, Mortensen SA, Rohde M, et al. High serum coenzyme Q10,
positively correlated with age, selenium and cholesterol, in Inuit of
Greenland. A pilot study. *Biofactors*. 1999;9:319-23.

74\. Pelton R, La Valle JB, Hawkins EB, Krinsky DL. Drug-Induced
Nutrient Depletion Handbook 1999-2000. Hudson, Ohio: Lexi-Comp, Inc;
1999:485.

75\. Pfizer reports 38% increase. *San Diego Union Tribune, January 24*.
San Diego; 2002.

76\. Sinzinger H. Does vitamin E beneficially affect muscle pains during
HMG-Co-A-reductase inhibitors without CK-elevation. *Atherosclerosis*.
2000;149:225.

77\. Sinzinger H, Chehne F, Lupattelli G. Oxidation Injury in Patients
Receiving HMG-CoA Reductase Inhibitors: Occurrence in Patients Without
Enzyme Elevation or Myopathy. *Drug Saf*. 2002;25:877-83.

78\. Sinzinger H, Schmid P, O\'Grady J. Two different types of
exercise-induced muscle pain without myopathy and CK -elevation during
HMG-Co-enzyme-A-reductase inhibitor treatment. *Atherosclerosis*.
1999;143:459-460.

79\. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory
loss. *Pharmacotherapy*. 2001;21:767-9.

80\. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on
cognitive function and psychological well-being. *Am J Med*.
2000;108:538-46.

81\. Bruckert E, Simonetta C, Giral P. Compliance with fluvastatin
treatment characterization of the noncompliant population within a
population of 3845 patients with hyperlipidemia. CREOLE Study Team. *J
Clin Epidemiol*. 1999;52:589-94.

82\. Gaist D, Jeppesen M, Andersen LA, Garcia Rodriguez J, Hallas J,
Sindrup SH. Statins and risk of polyneuropathy: A case-control study.
*Neurology*. 2002;58:1333-1337.

83\. Blasiak J, Walter Z. Protective action of cholesterol against
changes in membrane fluidity induced by malathion. *Acta Biochimica
Polonica*. 1992;39:49-52.

84\. Nevin DN, Zambon A, Furlong CE, et al. Paraoxonase genotypes,
lipoprotein lipase activity, and HDL. *Arterioscler Thromb Vasc Biol*.
1996;16:1243-9.

85\. Kishi H, Kishi T, Folkers K. Bioenergetics in clinical medicine.
III. Inhibition of coenzyme Q10-enzymes by clinically used
anti-hypertensive drugs. *Res Commun Chem Pathol Pharmacol*.
1975;12:533-40.

86\. Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine
XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic
blockers of beta-receptors. *Res Commun Chem Pathol Pharmacol*.
1977;17:157-64.

87\. Reyes AJ, Leary WP, Lockett CJ, Alcocer L. Diuretics and zinc. *S
Afr Med J*. 1982;62:373-5.

88\. Cohanim M, Yendt ER. The effects of thiazides on serum and urinary
zinc in patients with renal calculi. *Johns Hopkins Med J*.
1975;136:137-41.

89\. Mountokalakis T, Dourakis S, Karatzas N, Maravelias C, Koutselinis
A. Zinc deficiency in mild hypertensive patients treated with diuretics.
*J Hypertens Suppl*. 1984;2:S571-2.

90\. Lockett CJ, Reyes AJ, Leary WP, Alcocer L, Olhaberry JV. Zinc,
angiotensin I-converting enzyme and hypertension. *S Afr Med J*.
1983;64:1022-4.

91\. Bunning P, Riordan JF. The functional role of zinc in angiotensin
converting enzyme: implications for the enzyme mechanism. *J Inorg
Biochem*. 1985;24:183-98.

92\. Reeves PG, O\'Dell BL. An experimental study of the effect of zinc
on the activity of angiotensin converting enzyme in serum. *Clin Chem*.
1985;31:581-4.

93\. Reeves PG, O\'Dell BL. Effects of dietary zinc deprivation on the
activity of angiotensin-converting enzyme in serum of rats and guinea
pigs. *J Nutr*. 1986;116:128-34.

94\. White CL, Pschorr J, Jacob IC, von Lutterotti N, Dahlheim H. The
effect of zinc in vivo and in vitro on the activities of angiotensin
converting enzyme and kininase-I in the plasma of rats. *Biochem
Pharmacol*. 1986;35:2489-93.

95\. Schullek JR, Wilson IB. The binding of zinc to
angiotensin-converting enzyme. *Arch Biochem Biophys*. 1988;265:346-50.

96\. Dahlheim H, White CL, Rothemund J, von Lutterotti N, Jacob IC,
Rosenthal J. Effect of zinc depletion on angiotensin I-converting enzyme
in arterial walls and plasma of the rat. *Miner Electrolyte Metab*.
1989;15:125-9.

97\. Kagan BL, Leskin G, Haas B, Wilkins J, et al. Elevated lipid levels
in Vietnam veterans with chronic posttraumatic stress disorder.
*Biological Psychiatry*. 1999;45:374-377.

98\. Peter H, Tabrizian S, Hand I. Serum cholesterol in patients with
obsessive compulsive disorder during treatment with behavior therapy and
SSRI or placebo. *International Journal of Psychiatry in Medicine*.
2000;30:27-39.

99\. Kuczmierczyk AR, Barbee JG, Bologna NA, Townsend MH. Serum
cholesterol levels in patients with generalized anxiety disorder (GAD)
and with GAD and comorbid major depression. *Canadian Journal of
Psychiatry*. 1996;41:465-8.

100\. Bajwa WK, Asnis GM, Sanderson WC, Irfan A, van Praag HM. High
cholesterol levels in patients with panic disorder. *American Journal of
Psychiatry*. 1992;149:376-378.

101\. Bajwa WK, Asnis GM, Sanderson WC, Irfan A, van Praag HM. High
cholesterol levels in patients with panic disorder. *Am J Psychiatry*.
1992;149:376-8.

102\. Hayward C, Taylor C, Roth W, King R, Agras W. Plasma lipid levels
in patients with panic disorder or agoraphobia. *Am J Psychiatry*.
1989;146:917-9.

103\. Patterson S, Gottdiener J, Hecht G, Vargot S, Krantz D. Effects of
acute mental stress on serum lipids: mediating effects of plasma volume.
*Psychosomatic Med*. 1993;55:525-32.

104\. Peterson J, Keith R, Wilcox A. Hourly changes in serum cholesterol
concentration: Effects of the anticipation of stress. *Circulation*.
1962;25:798-803.

105\. Thomas C, Murphy E. Further studies on cholesterol levels in the
Johns Hopkins medical students: the effect of stress at examinations. *J
Chron Dis*. 1958;8:661-8.

106\. Wertlake P, Wilcox A, Haley M, Peterson J. Relationship of mental
and emotional stress to serum cholesterol levels. *Proc Soc Exper Biol &
Med*. 1958;97:163.

107\. Muldoon M, Herbert T, Patterson S, Kameneva M, Raible R, Manuck S.
Effects of acute psychological stress on serum lipid levels,
hemoconcentration, and blood viscosity. *Arch Intern Med*.
1995;155:615-20.

108\. Muldoon M, Bachen E, Manuck S, Waldstein S, Bricker P, Bennett J.
Acute cholesterol responses to mental stress and change in posture.
*Arch Intern Med*. 1992;152:775-80.

109\. McCabe W, Hammarsten J, Scjhottstaedt W, Adsett C, Yamamoto J,
Wold S. Elevations of serum cholesterol in man in association with life
stress and independent of diet and exercise. *Abstract, J. Lab & Clin
Med*. 1959;54:922.

110\. Dreyfuss F, Czaczkes J. Blood cholesterol and uric acid of healthy
medical students under the stress of an examination. *Ann Intern Med*.
1959;103:708-11.

111\. Muldoon M, Herbert T, Patterson S, Kameneva M, Raible R, Manuck S.
Effects of acute psychological stress on serum lipid levels,
hemoconcentration, and blood viscosity. *Arch Intern Med*.
1995;155:615-20.

112\. Patterson S, Gottdiener J, Hecht G, Vargot S, Krantz D. Effects of
acute mental stress on serum lipids: mediating effects of plasma volume.
*Psychosomatic Med*. 1993;55:525-32.

113\. Hata S, Kunida H, Oyama Y. \[Antihypertensive effects of coenzyme
Q10 in essential hypertension\--in relation to the renin-aldosterone
system\]. *Horumon To Rinsho*. 1977;25:1019-23.

114\. Hamdy BH, Elnokaly F, Gaafar S, Elnaggar B, Hussein L.
Effectiveness of periodic oral vitamin A dosage on hypovitaminosis in
Egypt. *Int J Vitam Nutr Res*. 1982;52:235-40.

115\. Marinho HA, Shrimpton R, Giugliano R, Burini RC. Influence of
enteral parasites on the blood vitamin A levels in preschool children
orally supplemented with retinol and/or zinc. *Eur J Clin Nutr*.
1991;45:539-44.

116\. Morris MC. *Archives of Neurology*. 2002;59:1125-32.

117\. Vitamin E slows cognitive decline in the elderly. *Internal
Medicine World Report*. 2002:4.

118\. Sato Y, Honda Y, Asoh T, Kikuyama M, Oizumi K. Hypovitaminosis D
and decreased bone mineral density in amyotrophic lateral sclerosis.
*Eur Neurol*. 1997;37:225-9.

119\. Prabhala A, Garg R, Dandona P. Severe myopathy associated with
vitamin D deficiency in western New York. *Arch Intern Med*.
2000;160:1199-203.

120\. Gennari A, Viviani B, Galli CL, Marinovich M, Pieters R, Corsini
E. Organotins induce apoptosis by disturbance of \[Ca(2+)\](i) and
mitochondrial activity, causing oxidative stress and activation of
caspases in rat thymocytes. *Toxicol Appl Pharmacol*. 2000;169:185-90.

121\. Ravikumar A, Arun P, Devi KV, Augustine J, Kurup PA. Isoprenoid
pathway and free radical generation and damage in neuropsychiatric
disorders. *Indian J Exp Biol*. 2000;38:438-46.